130 related articles for article (PubMed ID: 38698698)
21. Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer.
Koizumi W; Boku N; Yamaguchi K; Miyata Y; Sawaki A; Kato T; Toh Y; Hyodo I; Nishina T; Furuhata T; Miyashita K; Okada Y
Ann Oncol; 2010 Apr; 21(4):766-771. PubMed ID: 19828562
[TBL] [Abstract][Full Text] [Related]
22. Phase I clinical and pharmacokinetic/pharmacogenetic study of a triplet regimen of S-1/irinotecan/oxaliplatin in patients with metastatic colorectal or gastric cancer.
Park SR; Hong YS; Lim HS; Seong MW; Kong SY; Kim SY; Park YI; Jung KH
Cancer Chemother Pharmacol; 2013 Nov; 72(5):953-64. PubMed ID: 23982118
[TBL] [Abstract][Full Text] [Related]
23. S-1 plus Raltitrexed for Refractory Metastatic Colorectal Cancer: A Phase II Trial.
Chen Y; Wu J; Cheng K; Li ZP; Luo DY; Qiu M; Gou HF; Yi C; Li Q; Wang X; Yang Y; Cao D; Shen YL; Bi F; Liu JY
Oncologist; 2019 May; 24(5):591-e165. PubMed ID: 30651398
[TBL] [Abstract][Full Text] [Related]
24. Comparison of the efficacy and safety of S-1-based and capecitabine-based regimens in gastrointestinal cancer: a meta-analysis.
Zhang X; Cao C; Zhang Q; Chen Y; Gu D; Shen Y; Gong Y; Chen J; Tang C
PLoS One; 2014; 9(1):e84230. PubMed ID: 24392116
[TBL] [Abstract][Full Text] [Related]
25. S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial.
Yamada Y; Denda T; Gamoh M; Iwanaga I; Yuki S; Shimodaira H; Nakamura M; Yamaguchi T; Ohori H; Kobayashi K; Tsuda M; Kobayashi Y; Miyamoto Y; Kotake M; Shimada K; Sato A; Morita S; Takahashi S; Komatsu Y; Ishioka C
Ann Oncol; 2018 Mar; 29(3):624-631. PubMed ID: 29293874
[TBL] [Abstract][Full Text] [Related]
26. Bolus 5-fluorouracil (5-FU) In Combination With Oxaliplatin Is Safe and Well Tolerated in Patients Who Experienced Coronary Vasospasm With Infusional 5-FU or Capecitabine.
Chakrabarti S; Sara J; Lobo R; Eiring R; Finnes H; Mitchell J; Hartgers M; Okano A; Halfdanarson T; Grothey A
Clin Colorectal Cancer; 2019 Mar; 18(1):52-57. PubMed ID: 30396850
[TBL] [Abstract][Full Text] [Related]
27. Phase II study of combination therapy with S-1 and irinotecan in patients with advanced colorectal cancer.
Goto A; Yamada Y; Yasui H; Kato K; Hamaguchi T; Muro K; Shimada Y; Shirao K
Ann Oncol; 2006 Jun; 17(6):968-73. PubMed ID: 16603600
[TBL] [Abstract][Full Text] [Related]
28. Capecitabine Versus Continuous Infusion Fluorouracil for the Treatment of Advanced or Metastatic Colorectal Cancer: a Meta-analysis.
Wu Z; Deng Y
Curr Treat Options Oncol; 2018 Nov; 19(12):77. PubMed ID: 30483908
[TBL] [Abstract][Full Text] [Related]
29. Survival after recurrence in patients with gastric cancer who receive S-1 adjuvant chemotherapy: exploratory analysis of the ACTS-GC trial.
Ito S; Ohashi Y; Sasako M
BMC Cancer; 2018 Apr; 18(1):449. PubMed ID: 29678146
[TBL] [Abstract][Full Text] [Related]
30. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study.
Boku N; Yamamoto S; Fukuda H; Shirao K; Doi T; Sawaki A; Koizumi W; Saito H; Yamaguchi K; Takiuchi H; Nasu J; Ohtsu A;
Lancet Oncol; 2009 Nov; 10(11):1063-9. PubMed ID: 19818685
[TBL] [Abstract][Full Text] [Related]
31. Safety and Efficacy of 7 Days on/7 Days off Versus 14 Days on/7 Days off Schedules of Capecitabine in Patients with Metastatic Colorectal Cancer: A Retrospective Review.
Bryson E; Sakach E; Patel U; Watson M; Hall K; Draper A; Davis C; Goyal S; Alese O; Akce M; Shaib W; El-Rayes B; Szabo S; Wu C
Clin Colorectal Cancer; 2021 Jun; 20(2):153-160. PubMed ID: 33741260
[TBL] [Abstract][Full Text] [Related]
32. S-1-based chemotherapy versus capecitabine-based chemotherapy as first-line treatment for advanced gastric carcinoma: a meta-analysis.
He MM; Wu WJ; Wang F; Wang ZQ; Zhang DS; Luo HY; Qiu MZ; Wang FH; Ren C; Zeng ZL; Xu RH
PLoS One; 2013; 8(12):e82798. PubMed ID: 24349363
[TBL] [Abstract][Full Text] [Related]
33. S-1 and irinotecan with or without bevacizumab versus 5-fluorouracil and leucovorin plus oxaliplatin with or without bevacizumab in metastatic colorectal cancer: a pooled analysis of four phase II studies.
Iwasa S; Nagashima K; Yamaguchi T; Matsumoto H; Ichikawa Y; Goto A; Yasui H; Kato K; Okita NT; Shimada Y; Yamada Y
Cancer Chemother Pharmacol; 2015 Sep; 76(3):605-14. PubMed ID: 26220845
[TBL] [Abstract][Full Text] [Related]
34. Combination therapy of bevacizumab with either S-1 and irinotecan or mFOLFOX6/CapeOX as first-line treatment of metastatic colorectal cancer (TRICOLORE): Exploratory analysis of RAS status and primary tumour location in a randomised, open-label, phase III, non-inferiority trial.
Denda T; Takashima A; Gamoh M; Iwanaga I; Komatsu Y; Takahashi M; Nakamura M; Ohori H; Sakashita A; Tsuda M; Kobayashi Y; Baba H; Kotake M; Ishioka C; Yamada Y; Sato A; Yuki S; Morita S; Takahashi S; Yamaguchi T; Shimada K
Eur J Cancer; 2021 Sep; 154():296-306. PubMed ID: 34304054
[TBL] [Abstract][Full Text] [Related]
35. Panitumumab in combination with irinotecan plus S-1 (IRIS) as second-line therapy for metastatic colorectal cancer.
Takaoka T; Kimura T; Shimoyama R; Kawamoto S; Sakamoto K; Goda F; Miyamoto H; Negoro Y; Tsuji A; Yoshizaki K; Goji T; Kitamura S; Yano H; Okamoto K; Kimura M; Okahisa T; Muguruma N; Niitsu Y; Takayama T
Cancer Chemother Pharmacol; 2016 Aug; 78(2):397-403. PubMed ID: 27342247
[TBL] [Abstract][Full Text] [Related]
36. A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancer.
Twelves C; Gollins S; Grieve R; Samuel L
Ann Oncol; 2006 Feb; 17(2):239-45. PubMed ID: 16344278
[TBL] [Abstract][Full Text] [Related]
37. Feasibility and efficacy of capecitabine and FOLFIRI in patients aged 65 years and older with advanced colorectal cancer: a retrospective analysis.
Stec R; Bodnar L; Szczylik C
J Cancer Res Clin Oncol; 2010 Feb; 136(2):283-92. PubMed ID: 19693536
[TBL] [Abstract][Full Text] [Related]
38. S-1 and irinotecan plus bevacizumab as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer: a multicenter phase II study in Japan (KSCC1102).
Miyamoto Y; Tsuji A; Tanioka H; Maekawa S; Kawanaka H; Kitazono M; Oki E; Emi Y; Murakami H; Ogata Y; Saeki H; Shimokawa M; Natsugoe S; Akagi Y; Baba H; Maehara Y
Int J Clin Oncol; 2016 Aug; 21(4):705-712. PubMed ID: 26746689
[TBL] [Abstract][Full Text] [Related]
39. Incidence and risk markers of 5-fluorouracil and capecitabine cardiotoxicity in patients with colorectal cancer.
Dyhl-Polk A; Vaage-Nilsen M; Schou M; Vistisen KK; Lund CM; Kümler T; Appel JM; Nielsen DL
Acta Oncol; 2020 Apr; 59(4):475-483. PubMed ID: 31931649
[No Abstract] [Full Text] [Related]
40. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.
Hegewisch-Becker S; Graeven U; Lerchenmüller CA; Killing B; Depenbusch R; Steffens CC; Al-Batran SE; Lange T; Dietrich G; Stoehlmacher J; Tannapfel A; Reinacher-Schick A; Quidde J; Trarbach T; Hinke A; Schmoll HJ; Arnold D
Lancet Oncol; 2015 Oct; 16(13):1355-69. PubMed ID: 26361971
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]